Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free STOK Stock Alerts

Stoke Therapeutics (STOK) Financials

Stoke Therapeutics logo
$28.91 -0.55 (-1.87%)
As of 09:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Stoke Therapeutics

Annual Income Statements for Stoke Therapeutics

This table shows Stoke Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -32 -52 -86 -101 -105 -89 -6.89
Consolidated Net Income / (Loss)		 -13 -32 -52 -86 -101 -105 -89 -6.89
Net Income / (Loss) Continuing Operations		 -13 -32 -52 -86 -101 -105 -89 -6.89
Total Pre-Tax Income 		-13 -32 -52 -86 -101 -105 -89 -6.89
Total Operating Income		 -13 -36 -53 -86 -104 -115 -101 -21
Total Gross Profit		 0.00 0.00 0.00 0.00 12 8.78 37 184
Total Revenue		 0.00 0.00 0.00 0.00 12 8.78 37 184
Operating Revenue		 0.00 0.00 0.00 0.00 12 8.78 37 184
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 13 36 53 86 117 124 138 205
Selling, General & Admin Expense		 4.41 12 21 32 39 41 49 67
Research & Development Expense		 8.37 24 32 54 78 82 89 138
Total Other Income / (Expense), net		 0.26 3.35 0.80 0.26 3.29 10 12 14
Interest & Investment Income		 0.27 3.35 0.70 0.12 3.12 9.91 13 14
Other Income / (Expense), net		 -0.01 0.00 0.10 0.14 0.17 0.17 -0.25 -0.05
Basic Earnings per Share		 ($17.65) ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Weighted Average Basic Shares Outstanding		 709.34K 17.97M 33.49M 36.74M 38.90M 43.99M 54.01M 59.22M
Diluted Earnings per Share		 ($17.65) ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Weighted Average Diluted Shares Outstanding		 709.34K 17.97M 33.49M 36.74M 38.90M 43.99M 54.01M 59.22M
Weighted Average Basic & Diluted Shares Outstanding		 709.34K 17.97M 33.49M 36.74M 44.15M 46.30M 54.08M 59.15M

Quarterly Income Statements for Stoke Therapeutics

This table shows Stoke Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -24 -27 -26 -26 -26 -11 113 -23 -38 -58 -50
Consolidated Net Income / (Loss)		 -25 -27 -26 -26 -26 -10 113 -23 -38 -58 -50
Net Income / (Loss) Continuing Operations		 -25 -27 -26 -26 -26 -10 113 -23 -38 -58 -50
Total Pre-Tax Income 		-25 -27 -26 -26 -26 -10 114 -23 -40 -58 -50
Total Operating Income		 -27 -30 -28 -29 -30 -14 111 -27 -43 -61 -53
Total Gross Profit		 3.31 2.80 4.22 4.83 4.89 23 159 14 11 1.40 6.23
Total Revenue		 3.31 2.80 4.22 4.83 4.89 23 159 14 11 1.40 6.23
Operating Revenue		 3.31 2.80 4.22 4.83 4.89 23 159 14 11 1.40 6.23
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 31 32 33 34 35 36 47 41 54 63 60
Selling, General & Admin Expense		 10 11 10 13 13 13 15 15 16 21 20
Research & Development Expense		 20 22 22 21 22 23 33 26 38 42 40
Total Other Income / (Expense), net		 2.69 2.63 2.00 3.65 3.57 3.17 2.92 3.82 3.47 3.51 3.42
Interest & Investment Income		 2.65 2.59 2.43 3.70 3.55 2.97 2.89 3.79 3.46 3.62 3.40
Other Income / (Expense), net		 0.04 0.04 -0.43 -0.05 0.03 0.20 0.03 0.03 0.00 -0.11 0.02
Income Tax Expense		 - - 0.00 0.00 0.00 - 1.28 0.00 -1.28 - 0.00
Basic Earnings per Share		 ($0.55) ($0.61) ($0.57) ($0.46) ($0.47) ($0.15) $1.95 ($0.40) ($0.65) ($1.02) ($0.79)
Weighted Average Basic Shares Outstanding		 44.27M 43.99M 46.25M 55.77M 56.34M 54.01M 57.86M 58.35M 58.61M 59.22M 63.06M
Diluted Earnings per Share		 ($0.55) ($0.61) ($0.57) ($0.46) ($0.47) ($0.15) $1.90 ($0.40) ($0.65) ($0.97) ($0.79)
Weighted Average Diluted Shares Outstanding		 44.27M 43.99M 46.25M 55.77M 56.34M 54.01M 59.40M 58.35M 58.61M 59.22M 63.06M
Weighted Average Basic & Diluted Shares Outstanding		 44.65M 46.30M 52.12M 52.65M 52.97M 54.08M 54.60M 54.80M 57.12M 59.15M 62.28M

Annual Cash Flow Statements for Stoke Therapeutics

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 104 117 65 -142 -31 78 -63 -44
Net Cash From Operating Activities		 -11 -31 -42 -67 -32 -81 -87 46
Net Cash From Continuing Operating Activities		 -11 -31 -42 -67 -32 -81 -87 46
Net Income / (Loss) Continuing Operations		 -13 -32 -52 -86 -101 -105 -89 -6.89
Consolidated Net Income / (Loss)		 -13 -32 -52 -86 -101 -105 -89 -6.89
Depreciation Expense		 0.21 0.45 0.89 0.97 1.55 2.47 2.18 1.77
Amortization Expense		 - - 0.00 0.14 -0.21 -0.33 -1.64 -1.13
Non-Cash Adjustments To Reconcile Net Income		 0.25 1.93 6.81 18 25 28 30 35
Changes in Operating Assets and Liabilities, net		 1.09 -1.11 2.33 0.05 43 -6.03 -28 16
Net Cash From Investing Activities		 -0.93 -1.63 -1.05 -76 -46 106 -107 -187
Net Cash From Continuing Investing Activities		 -0.93 -1.63 -1.05 -76 -46 106 -107 -187
Purchase of Property, Plant & Equipment		 -0.94 -1.64 -1.05 -1.20 -3.96 -1.62 -0.20 -0.67
Purchase of Investments		 - - 0.00 -87 -201 0.00 -167 -323
Sale and/or Maturity of Investments		 - - 0.00 12 159 108 60 137
Net Cash From Financing Activities		 116 150 108 1.28 46 53 131 97
Net Cash From Continuing Financing Activities		 116 150 108 1.28 46 53 131 97
Issuance of Common Equity		 0.00 152 106 0.51 46 53 0.53 1.00
Other Financing Activities, net		 0.02 0.32 2.84 0.78 0.49 0.37 131 96
Cash Interest Paid		 - - - - - - 0.00 0.00

Quarterly Cash Flow Statements for Stoke Therapeutics

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.08 1.47 -13 15 -43 -22 147 -173 -18 0.83 74
Net Cash From Operating Activities		 -17 -21 -25 -17 -22 -23 132 -25 -30 -30 -61
Net Cash From Continuing Operating Activities		 -17 -21 -25 -17 -22 -23 132 -25 -30 -30 -61
Net Income / (Loss) Continuing Operations		 -25 -27 -26 -26 -26 -10 113 -23 -38 -58 -50
Consolidated Net Income / (Loss)		 -25 -27 -26 -26 -26 -10 113 -23 -38 -58 -50
Depreciation Expense		 0.64 0.62 0.56 0.55 0.54 0.53 0.48 0.45 0.44 0.41 0.44
Amortization Expense		 -0.12 -0.09 -0.02 -0.29 -0.55 -0.78 -0.49 0.53 -0.62 -0.55 -0.37
Non-Cash Adjustments To Reconcile Net Income		 7.12 6.65 5.96 7.99 8.07 7.72 7.35 8.21 9.27 11 9.36
Changes in Operating Assets and Liabilities, net		 -0.35 -0.88 -4.69 -0.03 -3.24 -20 12 -11 -1.12 17 -20
Net Cash From Investing Activities		 15 15 9.99 -88 -30 0.82 14 -148 9.09 -61 51
Net Cash From Continuing Investing Activities		 15 15 9.99 -88 -30 0.82 14 -148 9.09 -61 51
Purchase of Property, Plant & Equipment		 -0.38 -0.23 -0.01 -0.05 -0.10 -0.04 -0.15 -0.15 -0.13 -0.23 -0.35
Purchase of Investments		 - - 0.00 - -50 -29 -19 -182 -24 -98 -9.85
Sale and/or Maturity of Investments		 15 15 10 - 20 30 33 33 33 37 61
Net Cash From Financing Activities		 0.56 7.34 1.72 121 8.16 0.57 1.37 0.55 3.12 92 84
Net Cash From Continuing Financing Activities		 0.56 7.34 1.72 121 8.16 0.57 1.37 0.55 3.12 92 84
Issuance of Common Equity		 0.35 7.34 1.47 - 8.02 0.00 0.37 - 0.63 - 81
Other Financing Activities, net		 0.21 0.00 0.25 121 0.14 0.57 1.00 0.55 2.49 92 3.21

Annual Balance Sheets for Stoke Therapeutics

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 108 229 298 239 256 228 272 418
Total Current Assets		 106 226 294 229 244 215 233 306
Cash & Equivalents		 105 222 287 145 114 191 128 84
Short-Term Investments		 - - 0.00 75 116 9.95 89 200
Note & Lease Receivable		 0.20 0.28 0.01 0.13 0.59 0.06 0.70 1.97
Accounts Receivable		 - - - - - - 1.67 5.94
Prepaid Expenses		 0.55 3.28 6.44 6.94 11 11 11 8.74
Other Current Assets		 - 0.00 0.18 2.33 2.96 2.56 2.30 4.39
Plant, Property, & Equipment, net		 1.19 2.51 2.68 4.14 6.68 5.82 3.91 3.15
Total Noncurrent Assets		 0.20 0.21 1.32 5.51 5.32 7.18 35 110
Long-Term Investments		 - - - - - 0.00 30 106
Other Noncurrent Operating Assets		 0.20 0.21 1.32 5.51 5.32 7.18 5.07 3.33
Total Liabilities & Shareholders' Equity		 108 229 298 239 256 228 272 418
Total Liabilities		 2.47 4.32 12 21 71 69 43 66
Total Current Liabilities		 2.47 4.10 11 17 31 31 40 58
Accounts Payable		 1.07 0.75 1.50 2.39 0.77 1.70 2.50 4.94
Accrued Expenses		 1.40 3.35 9.93 15 16 14 19 41
Current Deferred Revenue		 - - - 0.00 15 15 19 12
Total Noncurrent Liabilities		 0.00 0.22 0.42 3.95 40 38 2.48 8.10
Noncurrent Deferred Revenue		 - - - 0.00 37 33 0.00 6.96
Other Noncurrent Operating Liabilities		 0.00 0.22 0.42 3.95 2.97 4.88 2.48 1.14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 105 224 286 218 185 160 229 352
Total Preferred & Common Equity		 105 224 286 218 185 160 229 352
Total Common Equity		 105 224 286 218 185 160 229 352
Common Stock		 131 282 396 414 483 561 720 850
Retained Earnings		 -26 -58 -110 -196 -297 -402 -491 -498
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.17 -1.18 -0.02 -0.15 0.54

Quarterly Balance Sheets for Stoke Therapeutics

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 278 282 257 240 205 308 293 407 385 360 443
Total Current Assets		 265 270 246 230 193 297 254 376 270 272 367
Cash & Equivalents		 113 190 192 190 179 193 150 275 101 83 156
Short-Term Investments		 138 63 39 25 0.00 89 89 83 146 165 188
Note & Lease Receivable		 0.40 0.49 0.14 0.10 0.01 0.31 0.69 0.61 1.62 1.59 1.69
Accounts Receivable		 - - - - - - - - - 9.25 4.45
Prepaid Expenses		 13 10 11 11 11 10 9.84 13 14 7.75 10
Other Current Assets		 0.00 5.88 3.70 4.27 3.96 4.29 3.81 5.04 6.87 5.54 6.88
Plant, Property, & Equipment, net		 7.16 6.79 6.47 6.22 5.28 4.77 4.33 3.61 3.34 3.08 3.40
Total Noncurrent Assets		 5.30 4.77 4.22 3.65 6.63 5.99 35 28 111 85 73
Long-Term Investments		 - - - - - - 30 23 107 80 67
Other Noncurrent Operating Assets		 5.30 4.77 4.22 3.65 6.63 5.99 5.42 4.55 3.94 4.43 5.72
Total Liabilities & Shareholders' Equity		 278 282 257 240 205 308 293 407 385 360 443
Total Liabilities		 73 68 67 67 65 65 61 57 50 52 48
Total Current Liabilities		 29 32 22 25 36 44 50 45 39 42 41
Accounts Payable		 1.91 4.30 1.56 3.08 2.10 3.95 2.49 2.19 4.31 5.87 6.84
Accrued Expenses		 14 14 12 13 13 15 16 24 26 30 24
Current Deferred Revenue		 13 13 8.06 8.74 21 26 32 18 8.75 5.76 10
Total Noncurrent Liabilities		 45 36 45 42 29 21 11 12 11 10 7.59
Noncurrent Deferred Revenue		 41 34 43 41 25 17 8.29 10 9.63 8.56 6.60
Other Noncurrent Operating Liabilities		 3.61 2.30 1.63 0.96 4.21 3.61 3.05 1.87 1.26 1.87 0.99
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 204 214 190 173 140 243 232 350 335 308 395
Total Preferred & Common Equity		 204 214 190 173 140 243 232 350 335 308 395
Total Common Equity		 204 214 190 173 140 243 232 350 335 308 395
Common Stock		 477 534 541 548 569 697 712 728 736 747 943
Retained Earnings		 -271 -320 -350 -375 -428 -454 -480 -378 -401 -440 -548
Accumulated Other Comprehensive Income / (Loss)		 -1.70 -0.60 -0.38 -0.15 0.00 -0.02 0.17 -0.10 0.10 0.45 -0.12

Annual Metrics And Ratios for Stoke Therapeutics

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 32,729,777.00 33,470,262.00 36,790,993.00 - - - 57,117,150.00
DEI Adjusted Shares Outstanding		 0.00 32,729,777.00 33,470,262.00 36,790,993.00 - - - 57,117,150.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.99 -1.56 -2.33 - - - -0.12
Growth Metrics		 - - - - - - - -
Profitability Metrics		 - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -8.95 -25 -37 -60 -73 -80 -71 -14
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -50.35% -30.98% -4.09%
Earnings before Interest and Taxes (EBIT)		 -13 -36 -53 -86 -104 -115 -102 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -35 -52 -85 -103 -112 -101 -20
Valuation Ratios		 - - - - - - - -
Leverage & Solvency		 - - - - - - - -
Liquidity Ratios		 - - - - - - - -
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -27 -34 -59 -30 -83 -95 6.78
Efficiency Ratios		 - - - - - - - -
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -0.33 1.96 -1.23 -2.03 -45 -42 -18 -39
Increase / (Decrease) in Invested Capital		 0.00 2.29 -3.19 -0.80 -43 2.92 24 -21
Book Value per Share		 $148.12 $6.86 $8.55 $5.92 $4.69 $3.57 $4.32 $6.17
Tangible Book Value per Share		 $148.12 $6.86 $8.55 $5.92 $4.69 $3.57 $4.32 $6.17
Total Capital		 105 224 286 218 185 160 229 352
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -105 -222 -287 -220 -230 -201 -247 -391
Capital Expenditures (CapEx)		 0.93 1.63 1.05 1.20 3.96 1.62 0.20 0.67
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.72 -0.54 -4.80 -7.73 -17 -17 -24 -37
Debt-free Net Working Capital (DFNWC)		 104 222 283 212 213 185 193 248
Net Working Capital (NWC)		 104 222 283 212 213 185 193 248
Net Nonoperating Expense (NNE)		 3.57 7.35 15 26 28 24 18 -7.53
Net Nonoperating Obligations (NNO)		 -105 -222 -287 -220 -230 -201 -247 -391
Total Depreciation and Amortization (D&A)		 0.21 0.45 0.89 1.12 1.34 2.14 0.54 0.64
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 32.94M 36.66M 37.36M 38.90M 43.99M 54.01M 59.22M
Adjusted Diluted Earnings per Share		 $0.00 ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 32.94M 36.66M 37.36M 38.90M 43.99M 54.01M 59.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.80) ($1.56) ($2.34) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 17.97M 33.49M 36.74M 44.15M 46.30M 54.08M 59.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.95 -25 -37 -60 -73 -80 -71 -14
Debt Service Ratios		 - - - - - - - -
Payout Ratios		 - - - - - - - -

Quarterly Metrics And Ratios for Stoke Therapeutics

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 54,077,739.00 54,596,924.00 54,797,418.00 57,117,150.00 59,150,790.00
DEI Adjusted Shares Outstanding		 - - - - - - 54,077,739.00 54,596,924.00 54,797,418.00 57,117,150.00 59,150,790.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - 2.09 -0.43 -0.70 -1.01 -0.85
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 13.87% -14.32% -18.17% 294.72% 47.94% 707.35% 3,661.12% 186.01% 117.25% - -96.07%
EBITDA Growth		 0.53% -8.75% -17.66% 11.07% -12.38% 52.74% 493.66% 9.72% -44.29% - -147.93%
EBIT Growth		 -0.32% -8.89% -16.85% 11.53% -10.23% 54.46% 486.35% 7.21% -43.75% - -147.99%
NOPAT Growth		 -0.32% -8.88% -14.91% 11.79% -10.17% 53.85% 653.84% 6.96% -43.62% - -133.99%
Net Income Growth		 6.01% -5.08% -16.98% 16.18% -7.69% 61.12% 527.99% 8.61% -45.09% - -144.30%
EPS Growth		 16.67% 6.15% -7.55% 33.33% 14.55% 75.41% 433.33% 13.04% -38.30% - -141.58%
Operating Cash Flow Growth		 21.74% 7.71% -15.03% 19.83% -25.22% -12.32% 636.62% -45.46% -40.49% - -145.96%
Free Cash Flow Firm Growth		 -183.95% -199.74% 29.99% 33.81% -0.71% -42.25% 575.35% -70.93% -82.60% - -150.51%
Invested Capital Growth		 13.23% 6.52% 4.05% 4.62% 11.04% 57.50% 20.72% 48.93% 44.71% - 46.73%
Revenue Q/Q Growth		 233.33% -15.33% 50.52% 14.59% 1.30% 362.08% 601.20% -91.29% -23.05% - 344.29%
EBITDA Q/Q Growth		 18.56% -8.74% 2.58% -3.08% -2.92% 54.27% 911.46% -123.64% -64.50% - 13.57%
EBIT Q/Q Growth		 18.15% -8.65% 2.52% -2.05% -1.99% 55.12% 927.03% -124.51% -57.99% - 13.24%
NOPAT Q/Q Growth		 18.12% -8.64% 4.11% -3.42% -2.25% 54.49% 1,250.75% -117.37% -57.84% - 13.06%
Net Income Q/Q Growth		 19.94% -9.84% 2.17% 2.57% -2.86% 60.34% 1,176.88% -120.80% -63.30% - 13.69%
EPS Q/Q Growth		 20.29% -10.91% 6.56% 19.30% -2.17% 68.09% 1,366.67% -121.05% -62.50% - 18.56%
Operating Cash Flow Q/Q Growth		 20.82% -19.62% -18.97% 28.86% -23.68% -7.30% 668.39% -119.28% -19.45% - -98.93%
Free Cash Flow Firm Q/Q Growth		 25.02% 7.07% 9.12% -4.52% -14.10% -31.25% 403.68% -137.58% -21.89% - -131.08%
Invested Capital Q/Q Growth		 -1.13% -0.26% 8.58% -2.90% 5.68% 52.10% -70.52% 33.71% -2.11% - 58.03%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 -806.47% -1,035.70% -670.33% -603.00% -612.63% -60.63% 70.16% -190.34% -406.89% - -856.09%
Operating Margin		 -823.28% -1,056.30% -672.96% -607.37% -613.06% -60.38% 70.15% -197.58% -405.30% - -857.57%
EBIT Margin		 -822.04% -1,054.80% -683.11% -608.36% -612.48% -59.49% 70.17% -197.38% -405.27% - -857.28%
Profit (Net Income) Margin		 -741.90% -962.44% -625.57% -531.88% -540.05% -46.35% 71.19% -169.96% -360.68% - -802.75%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.88% 100.00% 96.77% - 100.00%
Interest Burden Percent		 90.25% 91.24% 91.58% 87.43% 88.17% 77.91% 102.60% 86.11% 91.96% - 93.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.12% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -54.83% -60.80% -61.29% -47.85% -52.06% -45.80% 20.50% 18.17% 15.02% - -45.58%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 -29.38% -38.24% -22.01% -32.66% -38.46% -8.70% 43.77% -113.99% -255.01% - -64.70%
Return on Assets (ROA)		 -26.52% -34.89% -20.15% -28.55% -33.91% -6.78% 44.41% -98.15% -226.95% - -60.58%
Return on Common Equity (ROCE)		 -54.83% -60.80% -61.29% -47.85% -52.06% -45.80% 20.50% 18.17% 15.02% - -45.58%
Return on Equity Simple (ROE_SIMPLE)		 -59.77% 0.00% -77.33% -42.67% -45.43% 0.00% 14.36% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -21 -20 -21 -21 -9.56 110 -19 -30 -43 -37
NOPAT Margin		 -576.29% -739.41% -471.07% -425.16% -429.14% -42.27% 69.37% -138.31% -283.71% - -600.30%
Net Nonoperating Expense Percent (NNEP)		 -2.35% -2.90% -3.01% -2.01% -2.24% -0.41% 1.03% -1.37% -2.74% - -3.19%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.98% - - - -4.17% 31.42% -5.71% -9.79% -12.20% -9.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 310.49% 378.79% 242.41% 269.86% 259.34% 56.80% 9.24% 110.46% 150.74% - 320.66%
R&D to Revenue		 612.79% 777.51% 530.55% 437.51% 453.72% 103.58% 20.61% 187.12% 354.55% - 636.91%
Operating Expenses to Revenue		 923.28% 1,156.30% 772.96% 707.37% 713.06% 160.38% 29.85% 297.58% 505.30% - 957.57%
Earnings before Interest and Taxes (EBIT)		 -27 -30 -29 -29 -30 -13 111 -27 -43 -62 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -29 -28 -29 -30 -14 111 -26 -43 -62 -53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.01 1.47 4.45 2.90 2.79 2.55 1.03 1.85 4.18 - 4.88
Price to Tangible Book Value (P/TBV)		 1.01 1.47 4.45 2.90 2.79 2.55 1.03 1.85 4.18 - 4.88
Price to Revenue (P/Rev)		 18.86 26.75 79.69 46.46 38.65 15.98 1.88 3.10 6.26 - 60.04
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 7.15 11.81 31.74 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.98% 8.47% 3.15% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 3.81 56.93 27.85 22.57 9.23 0.00 1.32 4.66 - 47.22
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.41 34.28 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.52 34.94 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.57 35.27 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.30 18.15 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.58 90.48 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.24 -1.25 -1.22 -1.19 -1.19 -1.15 -1.14 -1.10 -1.11 - -1.06
Leverage Ratio		 1.37 1.41 1.38 1.30 1.32 1.29 1.25 1.20 1.21 - 1.14
Compound Leverage Factor		 1.24 1.28 1.26 1.14 1.16 1.00 1.28 1.03 1.11 - 1.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 0.07 0.17 3.36 5.15 4.60 6.53 4.85 7.05 14.05 - 22.70
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.13 6.99 5.43 6.67 5.09 5.81 8.41 6.98 6.53 - 8.99
Quick Ratio		 8.52 6.54 5.02 6.34 4.81 5.43 8.01 6.45 6.21 - 8.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -24 -21 -22 -26 -34 102 -38 -47 -22 -52
Operating Cash Flow to CapEx		 -4,507.05% -9,017.03% -204,716.67% -37,993.48% -20,985.44% -55,221.43% 86,728.29% -16,507.79% -23,004.55% - -17,162.04%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.04 0.03 0.05 0.06 0.15 0.62 0.58 0.63 - 0.08
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 1.38 1.41 1.30 2.70 3.17 7.51 42.95 49.28 55.46 - 9.16
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -42 -42 -38 -39 -37 -18 -30 -20 -21 -39 -16
Invested Capital Turnover		 -0.21 -0.20 -0.20 -0.38 -0.42 -1.23 -5.57 -6.73 -7.14 - -1.38
Increase / (Decrease) in Invested Capital		 6.36 2.92 1.61 1.90 4.61 24 7.93 19 17 -21 14
Enterprise Value (EV)		 -40 33 447 422 378 337 -21 265 959 - 1,515
Market Capitalization		 174 235 625 704 647 584 360 620 1,288 - 1,926
Book Value per Share		 $3.91 $3.57 $3.03 $4.66 $4.41 $4.32 $6.47 $6.13 $5.62 $6.17 $6.68
Tangible Book Value per Share		 $3.91 $3.57 $3.03 $4.66 $4.41 $4.32 $6.47 $6.13 $5.62 $6.17 $6.68
Total Capital		 173 160 140 243 232 229 350 335 308 352 395
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -215 -201 -179 -282 -269 -247 -380 -355 -329 -391 -411
Capital Expenditures (CapEx)		 0.38 0.23 0.01 0.05 0.10 0.04 0.15 0.15 0.13 0.23 0.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.90 -17 -21 -30 -36 -24 -26 -16 -18 -37 -18
Debt-free Net Working Capital (DFNWC)		 205 185 158 252 204 193 331 231 231 248 326
Net Working Capital (NWC)		 205 185 158 252 204 193 331 231 231 248 326
Net Nonoperating Expense (NNE)		 5.48 6.25 6.51 5.16 5.43 0.92 -2.88 4.37 8.18 15 13
Net Nonoperating Obligations (NNO)		 -215 -201 -179 -282 -269 -247 -380 -355 -329 -391 -411
Total Depreciation and Amortization (D&A)		 0.52 0.54 0.54 0.26 -0.01 -0.26 -0.02 0.97 -0.17 -0.15 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 -107.05% -192.19% -266.39% -195.03% -212.21% -66.40% -13.80% -8.25% -8.56% - -55.08%
Debt-free Net Working Capital to Revenue		 2,214.73% 2,101.59% 2,010.26% 1,665.99% 1,216.98% 527.15% 173.41% 115.71% 112.20% - 1,015.82%
Net Working Capital to Revenue		 2,214.73% 2,101.59% 2,010.26% 1,665.99% 1,216.98% 527.15% 173.41% 115.71% 112.20% - 1,015.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.55) ($0.61) ($0.57) ($0.46) ($0.47) ($0.15) $1.95 ($0.40) ($0.65) ($1.02) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding		 44.27M 43.99M 46.25M 55.77M 56.34M 54.01M 57.86M 58.35M 58.61M 59.22M 63.06M
Adjusted Diluted Earnings per Share		 ($0.55) ($0.61) ($0.57) ($0.46) ($0.47) ($0.15) $1.90 ($0.40) ($0.65) ($0.97) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 44.27M 43.99M 46.25M 55.77M 56.34M 54.01M 59.40M 58.35M 58.61M 59.22M 63.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 44.65M 46.30M 52.12M 52.65M 52.97M 54.08M 54.60M 54.80M 57.12M 59.15M 62.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -21 -20 -21 -21 -9.56 110 -19 -30 -43 -37
Normalized NOPAT Margin		 -576.29% -739.41% -471.07% -425.16% -429.14% -42.27% 69.37% -138.31% -283.71% - -600.30%
Pre Tax Income Margin		 -741.90% -962.44% -625.57% -531.88% -540.05% -46.35% 71.99% -169.96% -372.70% - -802.75%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Stoke Therapeutics’ first quarter of 2026 shows a company still firmly in development-stage mode: meaningful revenue, heavy operating losses, and a balance sheet that remains well capitalized. The quarter was highlighted by a sharp step-up in revenue versus the prior quarter, but expenses remained much larger than sales, so profitability is still out of reach.

Top takeaways for retail investors:

  • Revenue rose to $6.2 million in Q1 2026, up sharply from $1.4 million in Q4 2025, showing a strong sequential improvement.
  • Cash, cash equivalents, and investments remained substantial at $411.0 million combined, giving the company a sizable liquidity cushion.
  • Stoke ended Q1 2026 with $744.4 million in net cash increase during the quarter, helped by $81.1 million of common equity issuance and strong investment sale activity.
  • The balance sheet is still strong, with $443.3 million in total assets versus $48.4 million in total liabilities.
  • Deferred revenue remains on the books, including $10.1 million in current deferred revenue and $6.6 million in noncurrent deferred revenue, indicating some future revenue recognition potential.
  • Interest and investment income contributed $3.4 million in Q1 2026, helping offset some operating losses.
  • Operating cash flow was still negative at -$60.6 million, reflecting the company’s ongoing cash burn.
  • Shares outstanding were higher than a year ago, and the quarter included equity issuance, which supports liquidity but adds dilution risk.
  • Net loss widened to -$50.0 million in Q1 2026, compared with -$38.3 million in Q3 2025 and -$57.9 million in Q4 2025, underscoring continued earnings pressure.
  • Operating expenses were $59.6 million against just $6.2 million of revenue, leaving a large operating loss of -$53.4 million.

Revenue and profitability trends: Stoke’s revenue has been lumpy over the last several years, which is common for a biotech company without a fully commercial product. In 2024 and early 2025, quarterly revenue ranged from roughly $4.2 million to $158.6 million, but that was followed by much lower revenue in the back half of 2025 and into Q1 2026. The latest quarter’s $6.2 million suggests improvement from the immediately preceding quarter, but the overall pattern remains volatile.

Losses remain the central story. In Q1 2026, research and development expense was $39.7 million and SG&A was $20.0 million. Those costs produced an operating loss of $53.4 million and a net loss of $50.0 million. That is a sign the company is still spending heavily to advance its pipeline rather than generating sustainable commercial cash flow.

Cash flow and balance sheet: The balance sheet remains the company’s biggest strength. As of March 31, 2026, Stoke had $155.7 million in cash and equivalents and $187.9 million in short-term investments, plus $67.5 million in long-term investments. Total liquidity of more than $410 million gives management runway, even though operating cash flow was negative. That said, the company also issued $81.1 million of common equity in the quarter, so part of that strength came with dilution.

Longer-term context: Compared with early 2024, Stoke’s balance sheet is still strong, but the share count and retained losses have both increased over time. Common stock on the balance sheet has climbed sharply, reflecting equity raises, while retained earnings remain deeply negative at -$547.7 million. For investors, that means the company has had access to capital, but it has not yet translated into durable profitability.

Bottom line: Stoke Therapeutics looks financially stable for now because of its cash and investment position, but the business is still in a high-burn phase. Investors should focus on two things from here: whether revenue can become less erratic and whether R&D spending begins to produce a clearer path toward commercialization.

07/14/26 07:03 AM ETAI Generated. May Contain Errors.

Stoke Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Stoke Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Stoke Therapeutics' net income appears to be on an upward trend, with a most recent value of -$6.89 million in 2025, falling from -$12.52 million in 2018. The previous period was -$88.98 million in 2024. Find out what analysts predict for Stoke Therapeutics in the coming months.

Stoke Therapeutics' total operating income in 2025 was -$20.59 million, based on the following breakdown:
  • Total Gross Profit: $184.42 million
  • Total Operating Expenses: $205.01 million

Over the last 7 years, Stoke Therapeutics' total revenue changed from $0.00 in 2018 to $184.42 million in 2025, a change of 18,442,000,000.0%.

Stoke Therapeutics' total liabilities were at $65.98 million at the end of 2025, a 55.1% increase from 2024, and a 2,570.1% increase since 2018.

In the past 7 years, Stoke Therapeutics' cash and equivalents has ranged from $84.22 million in 2025 to $287.31 million in 2020, and is currently $84.22 million as of their latest financial filing in 2025.

Over the last 7 years, Stoke Therapeutics' book value per share changed from 148.12 in 2018 to 6.17 in 2025, a change of -95.8%.


Related Companies

Financial statements for NASDAQ:STOK last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel